The regulation of protein stability by the ubiquitinproteasome pathway is a critical issue central to the comprehension of the molecular basis of carcinogenesis. However, ubiquitin modification of target substrates signals many cellular processes other than proteolysis that are also important for the development of cancer. It is noteworthy that many proteins studied by clinical breast cancer researchers are involved in these ubiquitin pathways. This review summarizes recent works on such proteins including cyclins, CDK inhibitors, and the SCF in cell cycle control; the breast and ovarian cancer suppressor BRCA1-BARD1; ErbB2/HER2/Neu and its ubiquitin ligase c-Cbl or CHIP; and the estrogen receptor and its downstream target Efp. Understanding these pathways may provide some hints toward developing diagnostic tools and treatments for breast cancer patients.
Introduction
The customary ubiquitin-proteasome proteolysis pathway is used to label proteins for rapid degradation. It consists of four critical enzymes: a ubiquitin-activating enzyme (E1), a ubiquitin-conjugating enzyme (E2 or UBC), a ubiquitin ligase (E3), and the 26S proteasome (reviewed in Hershko and Ciechanover, 1998) (Figure 1 ). E1 binds to and activates ubiquitin in an ATPdependent manner via a thiolester bond and then passes ubiquitin to an E2. E2 transfers ubiquitin to a lysine residue in the substrate via a terminal isopeptide bond through the E3. E3 is a scaffold protein that bridges in the substrate and the ubiquitin-linked E2. The resulting covalent ubiquitin ligations form polyubiquitinated conjugates that are rapidly detected and degraded by the 26S proteasome.
Recent studies revealed roles for ubiquitination other than proteolysis. While Lys-48 (K48)-linked polyubiquitin chains serve as a signal for proteasome-dependent degradation, monoubiquitination is a signal for endocytosis or subnuclear trafficking; K63-linked polyubiquitin chains signal endocytosis, IKK activation, ribosome modification, or DNA repair (reviewed in Pickart, 2001) (Figure 1 ). In all of these processes, the E3 enzyme provides the substrate specificity. Thus, there is a specific E3 for each substrate. Recent molecular dissection of many E3 ubiquitin ligase complexes revealed some common motifs such as the F-box protein in SCF complexes, RING fingers, HECT (Homology with E6-AP Carboxyl Terminus) domains, and U-boxes. Surprisingly, a number of well-studied proteins in the clinical breast cancer field that act as oncogenes, tumor suppressor genes, or prognostic factors are major participants in the ubiquitination pathway (Table 1) . In this review, we provide a comprehensive summary of ubiquitin-dependent regulation with regard to issues only specific to breast cancer. For information on proteins involved in ubiquitin-dependent regulation related to cancer in general (e.g. MDM2), please refer to other reviews in this issue.
Cell cycle regulators
The ubiquitin-proteasome proteolysis pathway regulates a number of cellular processes where rapid and irreversible reaction is required. Among them is cell cycle control. While cyclin-dependent kinases (CDKs) are stable during the cell cycle, cyclins and the p21 family of CDK inhibitors (CKIs) are temporally expressed (reviewed in Koepp et al., 1999) . Their relative levels determine whether CDKs are active or inactive, respectively. This temporal expression is mediated by ubiquitin-proteasome-dependent degradation. Cyclins and CKIs, whose expression levels are altered in breast cancer, include cyclin D1, cyclin E1, and p27. Importantly, these are cell cycle proteins that regulate the commitment of cell cycle progression at the G1/S transition.
At the protein level, cyclin D1 is overexpressed in 30-50% of human breast cancers and is considered to be a bona fide breast cancer oncogene (Musgrove et al., 1994; Wang et al., 1994; McIntosh et al., 1995) . High cyclin E1 protein expression significantly correlated with a poor outcome for breast cancer patients. Its hazard ratio for death was seven times as high as the hazard ratio associated with lymph-node metastases, which has been the best independent prognostic factor for breast cancer (Keyomarsi et al., 2002) . In contrast, the level of p27 protein is reduced in primary breast cancers, and these low levels predict a poor prognosis (Catzavelos et al., 1997; Porter et al., 1997; Tan et al., 1997) . However, when evaluating all these factors at the gene expression level, the prognostic value is controversial. For example, current studies of breast cancer gene expression profiling using DNA microarray showed that none of these genes, including cyclin E1, were related to a poor prognosis (van 't Veer et al., 2002) . One possible interpretation for this is that expression at the mRNA level and at the protein level of these genes differs critically, implicating that the mechanics of protein degradation are abrogated. Thus, it is important to elucidate the mechanisms that regulate the degradation of these gene products.
Investigation into these mechanisms revealed that the E3 ubiquitin ligase that regulates the G1/S transition is an SCF complex (Feldman et al., 1997; Skowyra et al., 1997) . The SCF consists of four subunits: SKP1, CUL1, an F-box protein, and ROC1/Rbx1/Hrt1 (Zheng et al., 2002) (Figure 2 ). ROC1 contains a RING finger domain that interacts with E2 and provides the ligase activity (Kamura et al., 1999; Ohta et al., 1999; Seol et al., 1999) . SKP1 functions as an adapter to connect the CUL1 scaffold to the F-box protein (Feldman et al., 1997; Skowyra et al., 1997) . F-box proteins are receptor subunits that provide the substrate selectivity and interact with, in most cases, phosphorylated substrates. There have been a number of F-box proteins identified, and each interacts with specific subsets of substrates.
The first identified F-box protein, Skp2, targets p27 to the SCF complex (Zhang et al., 1995; Carrano et al., 1999; Sutterlu¨ty et al., 1999) (Figure 2 ). Skp2 specifically recognizes p27 in a phosphorylation-dependent manner (Carrano et al., 1999) . Mice lacking Skp2 exhibit increased accumulation of p27 (Nakayama et al., 2000) . Consistent with its cellular role, Skp2 is overexpressed in a variety of human malignancies including breast cancer, and logically, the expression of Skp2 is Figure 1 Overview of the ubiquitin pathway utilized by RING type E3 ligases that directly interact with E2. The E1-E2-E3 cascade mediates ubiquitination of the substrate with the substrate specificity provided by the E3 enzyme. The ubiquitinated substrates are directed to either proteasome-dependent degradation or other functions depending upon the type of ubiquitination. -S-: thiolester bond
Figure 2 G1/S mediators that are altered in breast cancer by aberrant SCF E3 ligases. The SCF consists of four subunits: SKP1, CUL1, an F-box protein, and ROC1. F-box proteins are receptor subunits, and each F-box protein interacts with specific substrates. The cellular role of cyclins, CKIs, and their specific F-box proteins is well correlated with clinical aspects of breast cancer (Gstaiger et al., 2001; Signoretti et al., 2002) . Forced expression of Skp2 abolished the effects of antiestrogen reagents on the proliferation of normal human mammary epithelial cells (Signoretti et al., 2002) . This suggests that deregulation of Skp2 expression might play a role in the development of oncogenic potential in breast carcinogenesis. The F-box protein required for Cyclin E1 degradation is hCdc4/Fbw7 (Koepp et al., 2001; Strohmaier et al., 2001) (Figure 2 ). hCdc4 resembles its yeast homologue Cdc4 that possesses a C-terminal WD-repeat to target yeast G1 cyclins for degradation. hCdc4 associates specifically with phosphorylated cyclin E1, catalysing its ubiquitination and degradation. Interestingly, the gene encoding hCDC4 is mutated in breast cancer cells that express high levels of cyclin E1 (Strohmaier et al., 2001) . This argues for the importance of maintaining functioning degradation pathways. Cyclin D1 is also degraded via the ubiquitin-proteasome pathway in a phosphorylation-dependent manner (Diehl et al., 1997) , although the F-box protein and its expression status in breast cancer remains to be determined. Thus, the cellular role of cyclins, CKIs, and their specific ubiquitin ligases is well correlated with clinical aspects of breast cancer (Figure 2 ). Therefore, a comprehensive study of gene expression from breast cancers using DNA microarray techniques could reveal genes involved in degradation pathways. Following that, the re-evaluation of these factors at the protein level may also be important.
Alterations in the scaffolding component of the SCF, the cullin family members, have also been implicated in breast cancer. One of the cullin members, CUL4A, is gene amplified and overexpressed in primary breast cancers (Chen et al., 1998) . The role of Cul4A in breast cancer is not clear at present, although it has been reported that it associates with the damaged DNAbinding protein (DDB), which is composed of two subunits, p125 and p48. This association is thought to stimulate the degradation of p48/DDB2 through the ubiquitin-proteasome pathway Nag et al., 2001) , suggesting that Cul4A may be involved with DNA repair machinery. CUL4A may also regulate the cell cycle and cellular differentiation since this gene is required for early embryonic development (Li et al., 2002) . Its forced expression inhibits granulocytic and macrophage differentiation of PLB-985 myeloid cells, promoting proliferation instead .
Through the course of investigations for cell cycle regulation by the ubiquitin ligases SCF and APC (anaphase promoting complex), a critical role for the RING finger subunit in ubiquitin ligase activity has become apparent (Kamura et al., 1999; Ohta et al., 1999) . As a RING finger protein, AO7, was isolated in a yeast two-hybrid screen using E2/UbcH5B as bait, several otherwise unrelated RING finger proteins were tested for ubiquitin ligase activity (Lorick et al., 1999) . They were shown to catalyse polyubiquitination, leading to a proposal that the RING finger is a general motif to generate E2/Ubc-dependent polyubiquitination (Lorick et al., 1999) . Indeed, a number of RING finger ubiquitin ligases involved in many important cellular processes have been identified. Some of these RING finger proteins are critical in breast carcinogenesis and are reviewed below.
BRCA1-BARD1 ubiquitin ligase
The breast and ovarian cancer susceptibility gene BRCA1 is probably the most intensively studied gene in the breast cancer field because of its clinical importance and its multiple functions. The BRCA1 gene encodes a protein of 1863 amino acids (Miki et al., 1994) . The protein consists of a RING-finger domain in its amino-terminal region, a region encoded by exon 11 that includes a nuclear localization signal and a domain that binds to many critical cellular proteins, and tandem BRCT domains in its C-terminal region. BRCA1 has been implicated in an amazingly diverse range of biological processes such as DNA repair, cell cycle control, transcriptional regulation, apoptosis, and centrosome duplication. To date, the only known biochemical function ascribed to BRCA1 is E3 ubiquitin ligase activity.
The N-terminal RING finger domain of BRCA1 interacts with another conformationally similar RING finger protein, BARD1 (Wu et al., 1996; Brzovic et al., 2001) . BARD1 also contains an N-terminal RING domain and C-terminal tandem BRCT domains (Wu et al., 1996) . BRCA1 acquires significant ubiquitin ligase activity when bound to BARD1 as a RING heterodimer (Hashizume et al., 2001) . Importantly, deleterious missense mutations in the RING-finger domain of BRCA1 found in familial breast cancer kindred all abolish the ubiquitin ligase activity of BRCA1-BARD1 (Hashizume et al., 2001; Ruffner et al., 2001; Brzovic et al., 2003) . This suggests a strong connection between BRCA1's ligase activity and its tumor suppressor function. The analysis of ubiquitin ligase activity of RING-domain mutations is important not only to investigate the biological function of BRCA1 but also to predict a person's predisposition to cancer, which may influence the need for prophylactic surgeries. Besides enhancing BRCA1's ubiquitin ligase activity, BARD1 is also critical for the stability of BRCA1 in vivo (Hashizume et al., 2001; Joukov et al., 2001; Xia et al., 2003) . Therefore, loss of BARD1 results in a phenotype similar to that of BRCA1 loss, that is early embryonic lethality and chromosomal instability (McCarthy et al., 2003) . Furthermore, germline mutations of BARD1 are found in breast and ovarian cancer patients (Thai et al., 1998) .
Although the ubiquitin ligase activity may well be important for BRCA1's role as a tumor suppressor, the manner in which the activity contributes to BRCA1's biological function remains to be determined. There are two issues critical to elucidate the role of the BRCA1-BARD1 ubiquitin ligase that we discuss. One is the type of polyubiquitin chain built by BRCA1-BARD1 and the biological consequence it signals. The other is the identity of its specific substrate(s).
The role for polyubiquitination differs widely, depending on the type of linkage (Figure 1 ). Several groups have demonstrated that BRCA1-BARD1 assembles different types of linkages. Chen et al. (2002) was the first to report that BRCA1-BARD1 assembles non-K48-linked polyubiquitin chains. This observation was confirmed by another group who reported that BRCA1-BARD1 assembles both K48-and K63-linked polyubiquitin chains (Xia et al., 2003) . However, in vitro studies utilizing a series of ubiquitin lysine mutants indicated that BRCA1-BARD1 predominantly catalyses K6-linked polyubiquitin chains (Wu-Baer et al., 2003) . Furthermore, analysis of BRCA1-BARD1-mediated polyubiquitin chains by mass spectrometry also identified the K6-linked branched ubiquitin fragment (Nshikawa et al., 2003) . The K6-linked chains are recognized by the 26S proteasome for deubiquitination in a ubiquitin-aldehyde-sensitive manner as opposed to degradation (Nshikawa et al., 2003) . These observations suggest that the ubiquitination mediated by BRCA1-BARD1 could signal a process other than degradation.
Ubiquitin ligase activity may be responsible for more than one of the biological properties attributed to BRCA1. Since BRCA1 interacts with a number of proteins and functions in a variety of cellular processes, there exist many candidate substrates for the BRCA1-BARD1 ubiquitin ligase. Here, we review the representative functions of BRCA1 while discussing the possible involvement of BRCA1-BARD1 ubiquitin ligase activity (Figure 3 ).
BRCA1 interacts with complexes that contain important mediators of DNA repair. Upon DNA insult by DNA replication inhibitors such as hydroxyurea or ultraviolet (UV) light, BRCA1 joins BARD1, Rad51, and PCNA at sites of damaged, replicating DNA (Scully et al., 1997a) . The interaction with RAD51, a homologue of the yeast protein involved in the repair of DNA double-strand breaks (DSBs) by homologous recombination, indicates a role for BRCA1 in DNA repair. This is further evidenced by the fact that brca1-deficient cells are unable to repair chromosomal DSBs by homologous recombination (Moynahan et al., 1999) . BRCA1 also interacts with the RAD50-MRE11-NBS1 complex through Rad50, another important DNA repair protein.
The RAD50-MRE11-NBS1 complex is a multisubunit endonuclease, and mutations in the genes that encode components of this complex result in DNA-damage sensitivity and genomic instability (Trujillo et al., 1998; Paull and Gellert, 1999) . Upon irradiation or treatment with hydroxyurea, BRCA1 colocalizes with RAD50-MRE11-NBS1 complexes at large nuclear foci that also contain PCNA (Zhong et al., 1999; Wang et al., 2000) .
The recruitment of BRCA1 with Rad50 or Rad51 to damaged DNA sites is signaled by phosphorylated variant histone H2AX (g-H2AX) (Paull et al., 2000) . As BARD1 is also found in these foci, BRCA1 may have some role as a ubiquitin ligase in the complex. Indeed, purified BRCA1-BARD1 stimulates the UbcH5c-mediated monoubiquitination of histone H2AX in vitro (Chen et al., 2002; Mallery et al., 2002) . BRCA1-BARD1 also catalyses monoubiquitination of other nuclear core histones in vitro, including histone H2A (Chen et al., 2002; Mallery et al., 2002) . Although the in vivo evidence for monoubiquitination of histones by BRCA1-BARD1 remains to be shown, the results indicate a possible role for the BRCA1-BARD1 Figure 3 Potential roles for the BRCA1-BARD1 E3 ligase in known BRCA1 functions. BRCA1 interacts with a number of proteins and functions in a variety of cellular processes including DNA repair, cell cycle control, transcriptional regulation, apoptosis, and centrosome duplication. The E3 ligase activity may be involved in more than one of these known functions. P: phosphorylation Ubiquitin & breast cancer T Ohta and M Fukuda ubiquitin ligase activity in DNA repair by chromatin modification (Figure 3 ). Further supporting this assumption, cancer-predisposing mutations within the BRCA1 RING domain that abolish its ubiquitin ligase activity are unable to reverse g-radiation hypersensitivity of brca1-null human breast cancer cells, HCC1937 (Ruffner et al., 2001) . In addition to DNA repair, BRCA1's ubiquitin ligase activity may regulate its role in chromatin modification in transcription. BRCA1 can transcriptionally activate the expression of p21WAF1/CIP1 in a p53-dependent (Zhang et al., 1998; Chai et al., 1999) or p53-independent manner (Somasundaram et al., 1997) ; however, both mechanisms inhibit cell cycle progression into the S phase. A dominant-negative mutant of BRG1, a subunit of the SWI/SNF-related chromatin-remodeling complex that interacts with BRCA1, can abrogate the p53-mediated transcription of p21 by BRCA1 (Bochar et al., 2000) . This exemplifies BRCA1's transcriptional control through the modulation of chromatin structure. Monoubiquitination of histones by BRCA1-BARD1 may play a role in this process. Alternatively, BRCA1-BARD1 may target a member of the SWI/SNF-related chromatin-remodeling complex for ubiquitination (Figure 3) .
Another example of BRCA1's role in transcriptional control is signaling apoptosis through induction of GADD45 (Harkin et al., 1999) . Under normal conditions, BRCA1 interacts with ZBRK1 in an obligate manner to repress transcription of GADD45 (Zheng et al., 2000a) . Upon DNA damage, ZBRK1 is ubiquitinated and degraded. This releases the transactivational repression of GADD45 and results in apoptosis. (Yun and Lee, 2003) . However, ubiquitination of ZBRK1 and its subsequent degradation is independent of BRCA1's ubiquitin ligase activity. Thus, chromatin modification is again the most likely process targeted by BRCA1's ubiquitin ligase activity (Figure 3) .
In contrast, BRCA1 has also been suggested to regulate transcriptional activity negatively during transcription-coupled DNA repair. Evidence has shown that the large subunit of RNA Polymerase (Pol) II is ubiquitinated and degraded after UV-irradiation or cisplatin treatment, leading to transcriptional arrest in vitro (Lee et al., 2002) . BRCA1 interacts with the RNA Pol II holoenzyme (Scully et al., 1997b) , thus the transcriptional arrest could be achieved through ubiquitination of RNA Pol II by BRCA1. However, since BRCA1-BARD1 assembles non-K48-linked polyubiquitin chains as described above, whether BRCA1-BARD1 also signals protein degradation must be determined.
In addition to nuclear events, BRCA1 has a crucial role in centrosome duplication. The hypophosphorylated form of BRCA1 is associated with centrosomes during mitosis, and it coimmunoprecipitates with gtubulin, a centrosomal component essential for the nucleation of microtubules (Hsu and White, 1998; Hsu et al., 2001) . Mouse embryonic fibroblast cells carrying a targeted deletion of BRCA1 exon 11 exhibit multiple, functional centrosomes that lead to unequal chromosome segregation, abnormal nuclear division, and cellular aneuploidy (Xu et al., 1999) . BRCA1 may target a protein in the centrosome for ubiquitination during the mitosis, which may protect the centrosome from aberrant, additional cycles of duplication.
Other evidence that connects BRCA1 to genomic instability is its association with FANCD2. This protein is mutated in Fanconi's anemia, which is a disease characterized by increased chromosomal instability, progressive pancytopenia, and cancer susceptibility. The activated, monoubiquitinated isoform of FANCD2 protein localizes with BRCA1 to ionizing radiationinduced nuclear foci (Garcia-Higuera et al., 2001). Interestingly, damaged DNA-inducible monoubiquitination of FANCD2 is impaired in brca1-deficient cells (Garcia-Higuera et al., 2001) . While this information suggests that FANCD2 is a putative substrate of the BRCA1-BARD1 ubiquitin ligase, a more recent study reported that siRNA-mediated knockdown of BRCA1 does not affect FANCD2 monoubiquitination. Rather, it results in defective targeting of FANCD2 to DNAdamaged sites (Vandenberg et al., 2003) .
BRCA1 is a substrate for several checkpoint protein kinases, suggesting a possible mechanism for controlling BRCA1 ligase activity. BRCA1 is phosphorylated by ATM, the gene mutated in ataxia telangiectasia, upon ionizing irradiation, or by ATM-related kinase (ATR) in response to DNA damage induced by UV light, hydroxyurea, or ionizing irradiation (Cortez et al., 1999; Tibbetts et al., 2000) . The phosphorylation occurs in a region that contains clusters of serine-glutamine residues, and it is functionally important because a mutated Brca1 lacking these phosphorylation sites failed to rescue the radiation hypersensitivity of a brca1-deficient cell line (Cortez et al., 1999; Tibbetts et al., 2000) . In addition to ATM and ATR, BRCA1 is phosphorylated by a human homologue of yeast checkpoint protein kinase, hCds1/Chk2, in response to DNA damage induced by ionizing irradiation (Lee et al., 2000) . Whether phosphorylation regulates the ubiquitin ligase activity of BRCA1-BARD1 is an interesting matter to be tested.
At present, the only known substrates polyubiquitinated by the BRCA1-BARD1 ubiquitin ligase are BRCA1 and BARD1 themselves (Chen et al., 2002) . Autoubiquitination of BRCA1 could be important for enhancing its own ubiquitin ligase activity. This was evidenced when the enhanced activity of BRCA1-BARD1 by autoubiquitination resulted in efficient monoubiquitination of histones in vitro (Mallery et al., 2002) .
Like BARD1, the ubiquitin carboxy-terminal hydrolase BAP1 also interacts with the BRCA1-RING finger (Jensen et al., 1998) . This suggests that the ubiquitin ligase function of BRCA1 may be tightly regulated by the activating enzyme BARD1 and deubiquitinating enzyme BAP1. Whether BAP1 binds to BRCA1-RING in a competing manner with BARD1 or as a trimer complex is not known. BAP1 does not function in the deubiquitination of autoubiquitinated BRCA1/BARD1 complexes (Mallery et al., 2002) . However, BAP1 may deubiquitinate the substrate of BRCA1 when BARD1 is not present.
In order to predict the function of the BRCA1-BARD1 ubiquitin ligase activity and its specific substrates, understanding the structure of the heterodimer is important. Recent analysis of the RING heterodimer by NMR spectroscopy revealed that the E2 ubiquitin carrier protein UbcH5c binds only to the BRCA1 RING domain and not to the BARD1 RING (Brzovic et al., 2003) . The cleft of the BARD1 RING is left available for interaction with other proteins. It could bind to a protein that regulates BRCA1-BARD1's ubiquitin ligase activity. Alternatively, it may be the site for substrate interaction. Other important information emerging from the structural analysis is that UbcH7 also interacts with the BRCA1 RING domain with similar affinity to UbcH5c, but it does so without resulting in ubiquitin-ligase activity. Thus, binding of E2 alone is not sufficient for BRCA1-dependent ubiquitinligase activity (Brzovic et al., 2003) . Although a multitude of studies have been reported for BRCA1, they still do not provide enough information to understand BRCA1's role in breast carcinogenesis. Elucidation of the mechanisms regulating and regulated by BRCA1-BARD1 ubiquitin ligase activity may reveal the major role of BRCA1 in this process.
Degradation of ErbB2/HER2/Neu by ubiquitin ligases
One of the latest major improvements in breast cancer treatment is molecular targeting therapy to ErbB2/ HER2/Neu, a growth factor receptor tyrosine kinase, by the antibody Trastuzumab. ErbB2 has been long implicated in breast carcinogenesis as an oncogene. It is overexpressed in breast cancers, and the extent of overexpression has prognostic value (reviewed in Harari and Yarden, 2000) . Ubiquitination has emerged as a physiological mechanism for downregulating growth factor receptors (GFRs), and this mechanism contributes to ErbB2 downregulation induced by therapeutic anti-ErbB2 antibodies.
Two different pathways mediate downregulation of GFR by ubiquitination: ligand-dependent and ligandindependent degradation. Ligand-dependent degradation of GFR is mediated by c-Cbl, a RING type E3 ubiquitin ligase. c-Cbl recognizes tyrosine-phosphorylated substrates, such as activated GFR, through its SRC homology 2 (SH2) domain and ubiquitinates the bound substrates through its RING domain (Joazeiro et al., 1999) . The RING finger domain of c-Cbl interacts with UbcH7 (Yokouchi et al., 1999; Waterman et al., 1999; Zheng et al., 2000b) . The best studied c-Cbl targeted GFR is the epidermal growth factor receptor (EGFR, also ErbB1). Autophosphorylation of EGFR at a lysosome-targeting motif allows recruitment of c-Cbl followed by tyrosine phosphorylation of c-Cbl, which enables receptor ubiquitination and degradation ). An oncogenic mutant of c-Cbl that lacks a part of the RING finger domain, 70Z-Cbl, markedly reduced the ligand-induced, UbcH7-mediated ubiquitination of the EGFR (Yokouchi et al., 1999) . Degradation of EGFR by ubiquitination is not directly mediated by the 26S proteasome. Instead, the principal role for the ubiquitination of EGFR is likely endocytic sorting and subsequent lysosomal degradation (Levkowitz et al., 1998; de Melker et al., 2001) . However, both the lysosome and the proteasome could be required in this process since inhibitors of either enzyme block the degradation (Levkowitz et al., 1998) .
In contrast to EGFR, ErbB2 is resistant to c-Cblmediated degradation (Muthuswamy et al., 1999) . ErbB2 prefers to dimerize with other members of the ErbB family. In breast cancer, ErbB2 consists of heterodimers mainly with EGFR or ErbB3. The ErbB2-containing heterodimers escape the normal inactivation process by avoiding the c-Cbl degradation pathway. c-Cbl is unable to associate with EGFR, while it is complexed with ErbB2. This is most likely because ErbB2 is unable to phosphorylate the c-Cbl-binding site on EGFR (Muthuswamy et al., 1999) . Intriguingly, it has been reported that the therapeutic antibodies to ErbB2 may recruit the c-Cbl ubiquitin ligase to its phosphorylation site and induce degradation of ErbB2 (Klapper et al., 2000) . The detailed mechanism for this process remains to be determined.
Ligand-independent degradation of GFR is mediated by a different E3 ubiquitin ligase, CHIP (carboxyl terminus of Hsc70/Hsp70-interacting protein). CHIP possesses a carboxyl-terminal U-box, a structure that resembles the RING finger but does not coordinate zinc ions . Its tetratricopeptide repeat (TPR) domain interacts with Hsp70 and Hsp90 and attenuates their chaperone functions (Connell et al., 2001) . Molecular chaperones recognize non-native proteins and aid in their correct folding. When unsuccessful, the misfolded proteins can be directed to degradation. The CHIP E3 ligase induces ubiquitination and proteasomal degradation of the glucocorticoid receptor, a well-characterized Hsp90 substrate (Connell et al., 2001) .
ErbB2 also serves as a substrate for the Hsp70/Hsp90-associated CHIP (Xu et al., 2002; Zhou et al., 2003) . The association of CHIP with ErbB2 through a chaperone intermediate results in ubiquitination and degradation of ErbB2. The presence of Hsp90-inhibitory ansamycin antibiotics such as geldanamycin potently stimulates this process (Xu et al., 2002; Zhou et al., 2003) . Thus, clinical trials are currently ongoing to test whether 17-allylamino-geldanamycin (17-AAG) is a useful drug for breast cancer therapy by targeting ErbB2 degradation in a manner different from that of the ErbB2 antibody Trastuzumab.
Estrogen receptor signaling regulated by ubiquitination
Estrogens display tissue-selective action that is of great importance in the development of normal breast tissues as well as breast cancer. The interaction of the ligand estrogen with the estrogen receptor, a nuclear hormone receptor, induces transcriptional activity of the receptor. Approximately half of breast cancers are positive for estrogen receptor a (ER a) and are thought to be estrogen dependent. ER a provides us not only with a powerful prognostic marker but also a useful target for the treatment of ER-positive breast cancer patients with antiestrogens. It has been more than three decades since ER a was discovered; however, the regulation of its transcriptional activation is still unclear. The ubiquitinproteasome proteolytic pathway is one mechanism involved in ER signaling.
Upon treatment of cells with estradiol, ubiquitination of ER a is enhanced (Nirmala and Thampan, 1995) . This ubiquitination is important for degradation of ER a by the proteasome-dependent proteolytic pathway, and it is also required for efficient ER a transactivation. Treatment of ER a-transfected HeLa cells with the proteasome inhibitor, MG132, stabilized ER a levels but impaired ER a-mediated transcription (Lonard et al., 2000) . Mutations in helix 12 of ER a, the critical core of the AF-2 function of the receptor that interacts with transcriptional coactivators such as SRC-1, abolished ligand-mediated degradation and transactivation of the receptor (Lonard et al., 2000; Preisler-Mashek et al., 2002) . Interestingly, some receptor antagonists including tomoxifen, which is an antiestrogen used in breast cancer therapy, stimulate proteasome-dependent proteolysis of ER a (Preisler-Mashek et al., 2002 , Pearce et al., 2003 . It is likely that the antiestrogen effect of such ligand antagonists is, at least in part, mediated by the modification of ubiquitin-proteasome-dependent degradation of ER a.
A subsequent question that emerges is, what is the E3 ubiquitin ligase in this process? As ligand interaction with ER a is the critical step, the ubiquitin ligase may not be very important to the process. However, targeting of a substrate by a ubiquitin ligase is specific, and small molecules inhibiting the interaction between the ubiquitin ligase and ER a may be useful as antiestrogens in breast cancer therapy. Therefore, it is beneficial to determine the E3 ligase responsible, and there are a couple of candidates.
First, the HECT ubiquitin ligase, E6-AP, was initially identified as a ubiquitin ligase for p53 in the presence of the E6 protein from human papilloma virus types 16 and 18. It directly interacts with members of the nuclear hormone receptor superfamily (Nawaz et al., 1999) . Under normal conditions without E6, E6-AP targets other substrates for ubiquitination, such as Src family members. Furthermore, E6-AP is overexpressed in mouse mammary tumors (Sivaraman et al., 2000) . The interaction between E6-AP and the nuclear hormone receptor is hormone-dependent and activates transcriptional activity (Nawaz et al., 1999) . However, the ubiquitin ligase function of E6-AP is dispensable for its ability to coactivate nuclear hormone receptors (Nawaz et al., 1999) , suggesting that ubiquitination of ER a may not be mediated by E6-AP. Another candidate could be BRCA1, since BRCA1 mediates transcriptional repression of ER a (Fan et al., 1999) . However, this BRCA1 transcriptional repression is ligand-independent (Zheng et al., 2001) . Hence, the bona fide ubiquitin ligase for ER a remains to be determined.
Identification of the downstream effectors of ER a required for cell proliferation is a critical issue to understand hormone-dependent breast carcinogenesis and to generate treatments for such cancers. One of the genes whose expression is upregulated by ER a upon estrogen stimulation is cyclin D1 (Sabbah et al., 1999) , whose significance has already been discussed. Another important downstream protein is the estrogen-responsive finger protein, Efp. Efp is predominantly expressed in various female organs and is essential for estrogendependent cell proliferation and organ development (Orimo et al., 1999) . Mice deficient for Efp display underdeveloped uteri and reduced estrogen responsiveness (Orimo et al., 1999) . Interestingly, Efp possesses a RING finger B-box coiled-coil (RBCC) motif and, like other RING finger proteins, displays potent ubiquitin ligase activity (Urano et al., 2002) . Efp targets the proteolysis of 14-3-3s (Urano et al., 2002) , a p53-inducible gene that inactivates the mitotic CDC2/cyclin B complex by sequestering it in the cytoplasm (Hermeking et al., 1997) . Overexpression of Efp in estrogendependent MCF7 breast cancer cells causes tumor formation in nude mice in the absence of estrogen (Urano et al., 2002) . Alternatively, estrogen-dependent tumor growth of MCF7 cells implanted in female nude mice is reduced by treatment with antisense Efp oligonucleotide (Urano et al., 2002) . These data suggest that Efp is a major downstream target of estrogen.
An important interpretation for the breast cancer clinic is that Efp could promote a switch from estrogendependent to estrogen-independent growth of breast cancer cells. Most estrogen antagonist-sensitive breast cancers switch to being insensitive after several rounds of the hormone therapy. Thus, Efp could be an ideal molecular target for the treatment of such breast cancers.
Conclusion and perspectives
In the last 3 years, studies on ubiquitination-related mechanisms in carcinogenesis have dramatically advanced, and the impact of ubiquitin pathways on a variety of cellular machinery related to breast cancer is now being elucidated. This review has attempted to summarize the most studied players in breast carcinogenesis. However, more and more pathways are being discovered. For example, one involves RNF11 and Smurf2 in TGFb signaling. RNF11, a small UbcH5a-interacting RING-H2 protein, is overexpressed in breast cancer (Subramaniam et al., 2003) . RNF11 interacts with Smurf2 HECT-type ubiquitin ligase, resulting in ubiquitination of both RNF11 and Smurf2. This interaction restores the transcriptional activity of TGFb probably by affecting the Smurf2-Smad7-TGFb interactions that mediate degradation of TGFb (Subramaniam et al., 2003) . Recent study in a model of breast cancer progression suggests that TGFb switches from tumor suppressor to prometastatic factor (Tang et al., 2003) . RNF11 may have a role in the process. The investigation of ubiquitin pathway will provide further explanations for those questions.
In parallel, finding therapeutic approaches for cancers defective in ubiquitination machinery is currently an attractive research avenue. A proteasome inhibitor, Valcade (PS-341), acts by forming a transition state intermediate with the chymotryptic active site of the 20S proteasome. The US FDA recently approved it for use because of its exceptional efficacy in multiple myeloma. A drawback to this approach is that inhibition of the proteasome, theoretically, could disrupt many cellular processes. Therefore, it is ideal to identify small molecules that inhibit the proliferation of cancer cells more specifically, for example, by targeting E3 ubiquitin ligases. Future work may allow us to develop such drugs to further improve breast cancer therapies.
